天新药业(603235.SH)：2025年中报净利润为3.56亿元

Core Insights - Tianxin Pharmaceutical (603235.SH) reported a total revenue of 1.122 billion yuan and a net profit attributable to shareholders of 356 million yuan for the first half of 2025 [1] - The company experienced a net cash inflow from operating activities of 342 million yuan [1] Financial Performance - The latest debt-to-asset ratio is 18.66%, which is an increase of 1.84 percentage points from the previous quarter and an increase of 3.48 percentage points year-on-year [3] - The latest gross profit margin stands at 47.83%, reflecting a decrease of 2.00 percentage points from the previous quarter [3] - The return on equity (ROE) is 7.61%, down by 0.37 percentage points compared to the same period last year [3] - The diluted earnings per share (EPS) is 0.82 yuan [3] Efficiency Metrics - The total asset turnover ratio is 0.20 times, ranking 114th among disclosed peers, which is a decrease of 0.01 times year-on-year, representing a decline of 5.59% [3] - The inventory turnover ratio is 0.98 times, ranking 150th among disclosed peers, with a decrease of 0.31 times year-on-year, indicating a decline of 24.09% [3] Shareholder Structure - The number of shareholders is 14,800, with the top ten shareholders holding a total of 398 million shares, accounting for 90.97% of the total share capital [3] - The largest shareholder is Xu Jiangnan, holding 46.5% of the shares [3]